New Delhi: Intas Pharmaceuticals has got approval from the Subject Expert Committee (SEC) functional under the Central Drug ...

Bio-Thera will obtain an upfront payment of $21m and could earn up to $143.5m in development and commercial milestones.

Gone are the days when private equity investments were considered entirely benign from an antitrust perspective. Over ...

Accord BioPharma Inc., the U.S. specialty division of Intas Pharmaceuticals Ltd., has reached an exclusive commercialization and license agreement with Bio-Thera Solutions for BAT2506, a biosimilar ...

Bio-Thera had entered into an exclusive licensing agreement with STADA Arzneimittel AG to commercialize BAT2506 in the European Union (UK), the United Kingdom (UK), Switzerland, and selected other ...

Among them, the cardiac, anti-diabetic, and gastrointestinal therapies saw high value growth of 10.9 per cent, 10.2 per cent, ...

Serplulimab is the world’s first anti-PD-1 monoclonal antibody (mAb) approved for first-line treatment of ES-SCLC; Serplulimab is the first and only anti-PD-1 mAb approved in th ...

The "Adalimumab, Infliximab, Etanercept and Trastuzumab Biosimilars Market Opportunities and Strategies to 2033" report has ...

London-headquartered Accord is one of the largest suppliers of chemotherapy products in Europe and is a wholly-owned subsidiary of India's Intas Pharma, which has annual revenues of around $3.4 ...

February is Heart Month, a time to focus on the health and well-being of Ontarians. In recognition of this, and in advance of the upcoming provincial election, we are calling on all political parties ...